Up next

Supplier News: Siegfried, Cellares, Alcami, Vetter & More 

The latest from CDMOs, CMOs, and suppliers featuring Siegfried, Cellares, Alcami, Recipharm, Veranova, iOrganBio and Coating Place.  

Chemicals/Chemical API Manufacturing 
* Siegfried to Acquire Drug-Substance Business of Noramco & Extracas Bioscience 
Biologics Manufacturing 
* Cellares Raises $257 M in Series D Financing 
* Alcami Acquires Analytical Testing Facility for Biologics 
Formulation Development/Drug Product Manufacturing 
* Vetter To Build $574 M Mfg Facility
* Recipharm Expands Mfg Facility for Beta-Lactam Tablets 
Appointments 
* Veranova Appoints New Chief Quality Officer 
* iOrganBio Appoints New Chief Operating Officer 
* Coating Place Appoints New President 

Chemicals/Chemical API Manufacturing 

Siegfried to Acquire Drug Substance Business of Noramco & Extracas Bioscience 
Siegfried, a CDMO of drug substances and drug products, has entered agreements with an affiliate of SK Capital Partners to acquire the drug-substance business of the Noramco Group and Extractas Bioscience.  

The acquired businesses include three small-molecule drug substances sites with approximately 400 employees:  

  • Noramco, a commercial-scale manufacturing site in Wilmington, Delaware. 
  • Purisys, a clinical active pharmaceutical ingredient (API) development and manufacturing facility in Athens, Georgia. 
  • Extractas Bioscience, a manufacturer of purified products based in Westbury, Tasmania, Australia. 

Siegfried plans to expand its synthesis business in the US by optimizing its controlled-substance capacity across the newly acquired Wilmington site and its nearby Pennsville, New Jersey, site.  

As a result of this sale, Halo Pharma, a CDMO of drug products purchased by Noramco in 2023, will become a stand-alone company. Halo Pharma was purchased by the Noramco Group from Cambrex in 2023. With the sale of the API-related assets of the Noramco Group, Halo will serve as a dedicated platform for drug product CDMO services. 

Subject to customary closing conditions, the transaction is expected to close later this year (2026). 

Source: Siegfried 

Biologics Manufacturing 

Cellares Raises $257 M in Series D Financing 
Cellares, a South San Francisco, California-based CDMO of cell therapies, has announced $257-million in Series D financing co‑led by investment funds managed by BlackRock and Eclipse, bringing the company’s total capital raised to $612 million. 

The Series D funding adds a new group of investors, including accounts advised by T. Rowe Price Investment Management, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, and Gates Frontier, alongside continued participation from existing backers DC Global Ventures, DFJ Growth, and Willett Advisors. 

The round will fund the global build-out of manufacturing facilities across South San Francisco, California; Bridgewater, New Jersey; Leiden, the Netherlands; and Kashiwa City, Japan. Cellares expects to support clinical manufacturing in the first half of 2026, with commercial-scale manufacturing beginning in 2027. 

Source: Cellares 

Alcami Acquires Analytical Testing Facility for Biologics 
Alcami, a CDMO of drug products and provider of analytical testing services, has acquired a 37,000-square-foot facility in Durham, North Carolina, which will serve as a hub for Alcami’s analytical and development capabilities. In October 2025, Alcami announced plans for a lab expansion at this site, scheduled for completion later this year (2026). This expansion will enhance Alcami’s ability to support a broad range of therapeutics, including biologics, peptides, proteins, oligonucleotides, and cell-and gene-therapy drug substances. 

Source: Alcami 

Formulation Development/Drug Product Manufacturing 

Vetter To Build $574 M Mfg Facility 
Vetter, a CDMO of aseptic filling and packaging, has announced plans to build a EUR 480-million ($574-million) production facility in the Saarland region of southwest Germany. Construction is scheduled to begin in the second quarter of 2026. Initially, approximately EUR 480 million ($574 million) have been allocated for the first construction phase of the new commercial production plant. Operations are expected to commence in 2031. 

The company acquired the approximately 95-acre industrial property in the city of Saarlouis at the end of 2024. Vetter sees the potential to create up to 2,000 jobs in the long term. The European Commission has approved up to EUR 47 million ($56 million) of state aid for project. 

In parallel, the company recently began construction on a new clinical production site in Des Plaines, Illinois.  

Source: Vetter 

Recipharm Expands Mfg Facility for Beta-Lactam Tablets 
Recipharm, a CDMO of drug substances and drug products, has developed a new manufacturing facility to meet regulatory expectations for non-bacterial beta-lactam medicines. Recipharm has additionally secured a partnership with a bio/pharmaceutical company to manufacture its non-bacterial beta-lactam tablets. The partnership includes the installation of new, specialized manufacturing capabilities at Recipharm’s site in Bengaluru, India.  

Source: Recipharm 

Appointments 

Veranova Appoints New Chief Quality Officer 
Veranova, a CDMO of small-molecule active pharmaceutical ingredients and intermediates, has appointed Jacquelyn Martin, currently Chief Quality and Regulatory Compliance Officer at Alcami, as the company’s new Chief Quality Officer.  

Martin has more than 20 years of quality leadership experience in the pharmaceutical and CDMO sectors, with expertise spanning multiple modalities. She most recently served as Chief Quality and Regulatory Compliance Officer at Alcami, where she oversaw a network of CDMO facilities and drove advancements in quality system maturity, inspection readiness, and quality culture. Prior to Alcami, she held quality leadership positions at Gilead Sciences, AAIPharma Services, and TriPharm Services, and has served as an advisor to multiple companies on compliance and operational transformation.

Source: Veranova 

iOrganBio Appoints New Chief Operating Officer 
iOrganBio, a new CDMO that launched in October 2025, has appointed Karol Jarzabek, Vice President of Portfolio Operations at QHP Capital, as Chief Operating Officer. 

Jarzabek has expertise in operational management and business transformation, supported by training in predictive analytics and experience deploying AI-enabled systems across organizations. Most recently, he served as Vice President of Portfolio Operations at QHP Capital. Prior to QHP Capital, Jarzabek held multiple senior leadership roles at Azurity Pharmaceuticals, including Vice President of Strategic Finance and President of Established Brands, where he led M&A execution, operational integration, and portfolio management efforts. 

Source; iOrganBio 

Coating Place Appoints New President 
Coating Place, a CDMO of microencapsulation services, has appointed Ajay Damani, currently CEO of Phunnel, as President of Coating Place, reporting to Chief Executive Officer Tim Breunig. Damani will also join the company’s Board of Directors. Damani brings extensive experience in the CDMO sector, with leadership roles spanning the pharmaceutical, nutraceutical, and animal-health industries.  

Source: Coating Place